Destiny Pharma appoints new CEO as Bill Love becomes CSO

Privately-held UK biotech firm Destiny Pharma has appointed Neil Clark as chief executive and member of the board of directors, effective immediately.

Concurrently, Destiny’s scientific founder and previous CEO, Dr Bill Love, has been appointed chief scientific officer, a new position at the company.

Mr Clark joins Destiny from Ergomed, a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. Mr Clark joined Ergomed as chief financial officer in January 2009 and was CFO at its initial public offering in July 2014 until his move to be full time CEO of Ergomed’s PrimeVigilance business in January 2016. Prior to Ergomed, he was at CeNeS Pharmaceuticals, a company focused on developing drugs for central nervous system disorders and pain control, as CFO and subsequently CEO until its sale in 2008. He has spent 20 years in private and public life science companies and has a range of international experience in drug research and development, as well as licensing and partnering.